Immuneonco Biopharmaceuticals (shanghai) Inc.
Clinical trials sponsored by Immuneonco Biopharmaceuticals (shanghai) Inc., explained in plain language.
-
New hope for rare leukemia: drug duo targets remission and survival
Disease control Recruiting nowThis phase 3 study tests whether adding the experimental drug IMM01 (timdarpacept) to standard chemotherapy (azacitidine) helps adults with newly diagnosed chronic myelomonocytic leukemia (CMML). About 170 participants will receive either the combo or a placebo plus azacitidine. …
Phase: PHASE3 • Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. • Aim: Disease control
Last updated Apr 29, 2026 11:44 UTC
-
New injection aims to stabilize dangerous heart plaques
Disease control Recruiting nowThis early-stage study tests an injectable drug called IMC-001 in 18 people who recently had a heart attack or unstable angina. The goal is to see if it can make fatty plaques in the arteries more stable and less likely to cause future problems. Participants receive either the dr…
Phase: EARLY_PHASE1 • Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. • Aim: Disease control
Last updated Apr 29, 2026 11:40 UTC